However, high expression of BCYRN1 was observed to be significantly associated with some advanced clinical features, including TNM stage (III-IV vs. I-II, OR = 2.52, 95% CI 1.18–5.37, p=0.017; Figure 3(f)), T stage of the tumor (III-IV vs. I-II, OR = 2.11, 95% CI 1.49–2.99, p=0.000; Figure 3(g)), and tumor distant metastasis (positive vs. negative, OR = 4.19, 95% CI 1.45–12.05, p=0.008; Figure 3(h)). This evidence concerns the gene BCYRN1 and neoplasm.